On Thursday, Shares of Ford Motor Co. (NYSE:F), gained 2.65% to $13.56.
The mobility company label came up recently as officials from the Dearborn, Mich.-based company were at Jefferson Community and Technical College to talk about the future of transportation, according to Bizjournals.
The number of mega cities — cities with more than 10 million people — is predictable to grow in the coming decades, said Frank MacKenzie, intellectual property counsel for Ford. So Ford is considering how it can solve problems related to traffic congestion, parking, air quality, and general urban transportation matters, he said.
The traffic solution Ford gave us recently was an electric bike. As traffic becomes denser in large cities, motorists are going to have to park farther away from their destinations, he said. Ford is developing and testing a folding electric bike that users can keep and charge in their trunks. Bizjournals Reports
The bike has a number of features you won’t likely find on your conventional bike. For instance, it can warn you if cars behind you are getting close and it can assist in pedaling. A user can plug a phone into the bike and use it for GPS navigation. As the user gets closer to the destination, the bike is programmed to take over more of the pedaling — that way, you don’t arrive at the office too sweaty, MacKenzie said.
Ford did a survey of Louisville drivers recently in which about half said they would be open to using an electric bike in conjunction with a vehicle to get to work.
Ford Motor Company manufactures and distributes automobiles worldwide. The company operates through two sectors, Automotive and Financial Services. The Automotive sector develops, manufactures, distributes, and services vehicles, parts, and accessories.
Shares of Merck & Co. Inc. (NYSE:MRK), inclined 0.97% to $54.95, during its last trading session.
Merck & Co., known as MSD outside the United States and Canada, in conjunction with the U.S. Consumer Product Safety Commission (CPSC) asked that all customers, counting patients, inspect all bottles of TEMODAR® (temozolomide) capsules and all bottles of Temozolomide capsules (generic) for potential cracks in the child-resistant bottle caps. The medicine is manufactured by Merck and distributed in the United States by Merck as TEMODAR. The Temozolomide capsules (generic) are manufactured and packaged by Merck but sold and distributed by Sandoz, the authorized generic partner, under the Sandoz label. In addition to these supplies, Merck also provides TEMODAR in the United States in sachets (or pouches); TEMODAR in sachets are not affected.
Merck believes that about 1,100 bottles out of an estimated 276,000 distributed bottles of TEMODAR and Temozolomide capsules (generic) could potentially have cracked caps. Those bottles could be at wholesalers, pharmacies, healthcare providers or with patients. The bottle label will say it is offered by Merck & Co. or by Sandoz (for the generic).
Merck & Co., Inc. provides health care solutions worldwide. The company offer therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases.
Finally, Immunomedics Inc. (NASDAQ:IMMU), ended its last trade with 3.70% gain, and closed at $1.96.
Immunomedics declared the appointment of Arthur S. Kirsch, 63, to its Board of Directors. Mr. Kirsch has over 30 years of experience working in the equity capital markets and has extensive knowledge of the healthcare and life sciences field. He is Chairman of the Board of Pozen Inc. since June 1, 2015, serving as a Director since 2004; he also has been Chairman of the Audit Committee and Head of the Planned Transaction Committee of Pozen.
Since 2005, Mr. Kirsch has been a Senior Advisor with the investment bank, GCA Savvian, LLC (formerly Perseus Group, LLC). Preceding to GCA Savvian, he was a Managing Director of Vector Securities, LLC, an investment and merchant banking firm specializing in bioscience, which later became a unit of Prudential Securities, Inc. Preceding to Vector, he was Chief Executive Officer of NatWest Securities U.S. From 1979 to 1990, Mr. Kirsch served as Executive Vice President of the Global Equity Division of Drexel Burnham Lambert. He also serves on the Board of Directors of PhysioSonics, Inc., a privately held company developing noninvasive neurological products.
Mr. Kirsch received his BA in finance from the University of Rhode Island, and an MBA in finance from Bernard M. Baruch College.
Immunomedics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune, and other diseases. The company is developing Yttrium-90-labeled clivatuzumab tetraxetan, which is in Phase III registration study used for the treatment of pancreatic cancer.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
